LOGIN  |  REGISTER

Baxter to Present at 7th Annual Evercore HealthCONx Conference

November 19, 2024 | Last Trade: US$24.54 0.69 2.89

DEERFIELD, Ill. / Nov 19, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time.

The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, June 3, 2025.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

C4 Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page